Dorr V, Doolittle G, Woodroof J
Division of Oncology, Department of Internal Medicine, University Kansas Medical Center, Kansas City, USA.
Am J Hematol. 1996 Jun;52(2):108-13. doi: 10.1002/(SICI)1096-8652(199606)52:2<108::AID-AJH7>3.0.CO;2-Y.
Aplastic anemia is a disorder characterized by pancytopenia and bone marrow hypocellularity. There is some evidence that aplastic anemia may be due to suppression of hematopoiesis by activated T-suppressor cells. Thus, immunosuppressive agents have been used as an alternative to bone marrow transplantation for treatment. We report on a unique case of a patient with aplastic anemia who was treated with a course of immunosuppression including cyclosporine (CSA), anti-thymocyte globulin (ATG), and prednisone. Five months after this treatment, the patient developed a B cell lymphoproliferative disorder which was successfully treated with radiation therapy. Prior reports of CSA-associated lymphoproliferative disorders have appeared in the literature as potential side effects of immunosuppression following transplantation. This is the first report of a lymphoproliferative disorder associated with immunosuppressive treatment of aplastic anemia in a nontransplant setting. Thus, when presenting options for treatment of aplastic anemia, lymphoproliferative disorders should be included as a rare complication of immunosuppressive therapy.
再生障碍性贫血是一种以全血细胞减少和骨髓细胞减少为特征的疾病。有证据表明,再生障碍性贫血可能是由于活化的抑制性T细胞抑制造血所致。因此,免疫抑制剂已被用作骨髓移植的替代治疗方法。我们报告了一例再生障碍性贫血患者的独特病例,该患者接受了包括环孢素(CSA)、抗胸腺细胞球蛋白(ATG)和泼尼松在内的一个疗程的免疫抑制治疗。治疗五个月后,该患者发生了B细胞淋巴增殖性疾病,经放射治疗成功治愈。既往文献中已报道CSA相关的淋巴增殖性疾病是移植后免疫抑制的潜在副作用。这是首例关于在非移植情况下与再生障碍性贫血免疫抑制治疗相关的淋巴增殖性疾病的报告。因此,在提出再生障碍性贫血的治疗方案时,淋巴增殖性疾病应作为免疫抑制治疗的一种罕见并发症被纳入考虑。